002198 ST嘉应制药
2026/09 - 九个月2025/122024/122023/122022/12

盈利能力分析
净资产收益率 ROE (%)0.2414.1292.7104.6026.219
总资产报酬率 ROA (%)0.2043.6112.4444.0515.313
投入资产回报率 ROIC (%)0.2253.9272.5834.3605.754

边际利润分析
销售毛利率 (%)56.51559.94059.93265.21065.332
营业利润率 (%)1.84910.3876.7147.5988.174
息税前利润/营业总收入 (%)2.1899.8016.3076.9927.471
净利润/营业总收入 (%)0.6417.9425.4796.4366.665

收益指标分析
经营活动净收益/利润总额(%)271.516115.807107.51696.055108.449
价值变动净收益/利润总额(%)-61.400-3.9882.6902.8151.304
营业外收支净额/利润总额(%)-60.282-5.033-0.648-2.900-5.454

偿债能力分析
流动比率 (X)5.2995.21512.15311.7596.720
速动比率 (X)4.4954.44710.28610.0445.728
资产负债率 (%)15.47215.4619.6099.97913.965
带息债务/全部投入资本 (%)3.0150.4390.3260.2251.349
股东权益/带息债务 (%)3,048.46521,622.07029,248.73742,454.2846,972.824
股东权益/负债合计 (%)546.311546.770940.724902.103616.087
利息保障倍数 (X)2.114-110.556-17.324-17.835-26.683

营运能力分析
应收账款周转天数 (天)174.166100.24483.53782.23466.325
存货周转天数 (天)169.807186.287202.617161.925122.591